Itraconazole (Sporanox®) for vulvovaginal candidiasis.
暂无分享,去创建一个
[1] M. Barbareschi,et al. Itraconazole: new horizons , 2002 .
[2] G. Ricci,et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. , 2001, American journal of obstetrics and gynecology.
[3] R. Summerbell,et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. , 2000, Journal of the American Academy of Dermatology.
[4] E. Ringdahl. Treatment of recurrent vulvovaginal candidiasis. , 2000, American family physician.
[5] A. Gupta,et al. Itraconazole and terbinafine in perspective. From petri dish to patient. , 1999, Postgraduate medicine.
[6] P. De Doncker. Itraconazole and terbinafine in perspective: from petri dish to patient. , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] T. Tamaya,et al. Comparative Study on the Effectiveness of Antifungal Agents in Different Regimens against Vaginal Candidiasis , 1998, Chemotherapy.
[8] C. R. Daniel,et al. Itraconazole for the treatment of onychomycosis. , 1998, International journal of dermatology.
[9] P. Stoffels,et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. , 1997, Journal of the American Academy of Dermatology.
[10] W. Chaim. Fungal vaginitis caused by nonalbicans species. , 1997, American journal of obstetrics and gynecology.
[11] A. Spinillo,et al. Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. , 1997, The Journal of reproductive medicine.
[12] H. Degreef,et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. , 1997, Journal of the American Academy of Dermatology.
[13] P. Marone,et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. , 1997, American journal of obstetrics and gynecology.
[14] G. Piérard,et al. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. , 1995, Journal of the American Academy of Dermatology.
[15] S. Higgins,et al. Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. , 1995, The British journal of clinical practice.
[16] J. Sobel,et al. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. , 1994, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[17] G. Creatsas,et al. Chronic or recurrent vaginal candidosis: short-term treatment and prophylaxis with itraconazole. , 1993, Clinical therapeutics.
[18] J. Sobel. Candidal Vulvovaginitis , 1993, Clinical obstetrics and gynecology.
[19] G. Stein,et al. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis , 1993, Antimicrobial Agents and Chemotherapy.
[20] I. Fong,et al. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. , 1992, Genitourinary medicine.
[21] J. Tobin,et al. Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. , 1992, Genitourinary medicine.
[22] J. Ortonne,et al. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. , 1992, Dermatology.
[23] L. Sobral,et al. Itraconazole versus placebo in the management of vaginal candidiasis , 1991, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[24] M. Plempel,et al. Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole , 1991, Mycoses.
[25] D. Steinhilber,et al. Effects of novel antifungal azole derivatives on the 5-lipoxygenase and cyclooxygenase pathway. , 1990, Arzneimittel-Forschung.
[26] R. Woestenborghs,et al. The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.
[27] I. Bergbrant,et al. Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. , 1989, Acta dermato-venereologica.
[28] J. Meyer,et al. Itraconazole in the treatment of acute vaginal candidiasis. , 1988, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[29] R. Hay,et al. First International Symposium on Itraconazole: A Summary , 1987 .
[30] F. Sanz,et al. Randomized Comparative Trial of Three Regimens of Itraconazole for Treatment of Vaginal Mycoses , 1987 .
[31] V. Schuermans,et al. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. , 1987, Reviews of infectious diseases.
[32] J. Heykants,et al. Itraconazole: pharmacologic studies in animals and humans. , 1987, Reviews of infectious diseases.
[33] J. Faergemann. Treatment of Sebopsoriasis with Itraconazole:Behandlung von Sebopsoriasis mit Itraconazole , 1985 .
[34] J. Faergemann. Treatment of sebopsoriasis with itraconazole. , 1985, Mykosen.
[35] P. Farr,et al. The response of seborrhoeic dermatitis to ketoconazole , 1984, The British journal of dermatology.
[36] J. Faergemann. Quantitative Culture of Pityrosporon Orbiculare , 1984, International journal of dermatology.
[37] J. Leyden,et al. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. , 1975, The Journal of investigative dermatology.